Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
30 Jun 2020

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
30 Jun 2020

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )
26 Jun 2020

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
26 Jun 2020

New CAR T therapy for relapsed and refractory ALL

Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
25 Jun 2020

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020